Cited by 1,496Genomics and Rare DiseasesCardiomyopathy and Myosin StudiesCardiac electrophysiology and arrhythmias

ClinGen — The Clinical Genome Resource

Open access
Rehm, Heidi L., Berg, Jonathan S., Brooks, Lisa D., Bustamante, Carlos D., Evans, James P., Landrum, Melissa J., Ledbetter, David H., Maglott, Donna R. +6 more·2015·New England Journal of Medicine

Abstract

On autopsy, a patient is found to have hypertrophic cardiomyopathy. The patient’s family pursues genetic testing that shows a “likely pathogenic” variant for the condition on the basis of a study in an original research publication. Given the dominant inheritance of the condition and the risk of sudden cardiac death, other family members are tested for the genetic variant to determine their risk. Several family members test negative and are told that they are not at risk for hypertrophic cardiomyopathy and sudden cardiac death, and those who test positive are told that they need to be regularly monitored for cardiomyopathy on echocardiography. Five years later, during a routine clinic visit of one of the genotype-positive family members, the cardiologist queries a database for current knowledge on the genetic variant and discovers that the variant is now interpreted as “likely benign” by another laboratory that uses more recently derived population-frequency data. A newly available testing panel for additional genes that are implicated in hypertrophic cardiomyopathy is initiated on an affected family member, and a different variant is found that is determined to be pathogenic. Family members are retested, and one member who previously tested negative is now found to be positive for this new variant. An immediate clinical workup detects evidence of cardiomyopathy, and an intracardiac defibrillator is implanted to reduce the risk of sudden cardiac death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmsr1406261

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clinical translation of rare disease technologies has benefited from information resources including open databases of genes, clinically interpreted variants, and patient records.

    “Clinical translation of these technologies has benefited from a series of information resources, including open databases of genes associated with rare disorders (for example, OMIM and ORPHANET)21, clinically interpreted variants (for example, ClinVar and ClinGen)22,23 and patient records (for example, DECIPHER and MyGene2 (https://mygene2.org/MyGene2))17.”

    From A brief history of human disease genetics (2020) · cites this paper as [23]

  • The remaining 29 are suggested to be due to a combination of incomplete penetrance, late onset of disease, mild symptoms not seeking medical attention, unrecognised technical issues with sequencing or annotation, or dubious evidence to support the gene-phenotype assignment.

    “We suggest that the remaining 29 are due to a combination of incomplete penetrance[12–16], late onset of disease (i.e. not yet having occurred), individuals with mild symptoms not seeking medical attention, unrecognised technical issues with sequencing or annotation (e.g. tissue specific alternative splicing), or dubious evidence to support the gene-phenotype assignment”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rehm, H. L., Berg, J. S., Brooks, L. D., Bustamante, C. D., Evans, J. P., Landrum, M. J., Ledbetter, D. H., Maglott, D. R., Martin, C. L., Nussbaum, R. L., Plon, S. E., Ramos, E. M., Sherry, S. T., & Watson, M. S.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Stanford Medicine (US)
  • National Institutes of Health (US)
  • Geisinger Health System (US)
  • University of California, San Francisco (US)
  • Baylor College of Medicine (US)
  • American College of Medical Genetics (US)
Venue
New England Journal of Medicine
Published
2015-06-04
Volume
372
Issue
23
Pages
2235-2242
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1644197353
Cited by
1,496
References
26
Citations by year
2026: 158 · 2025: 194 · 2024: 163 · 2023: 130 · 2022: 175 · 2021: 133 · 2020: 110 · 2019: 91 · 2018: 116 · 2017: 86 · 2016: 92 · 2015: 43 · 2013: 1
FWCI
76.65
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • New England Journal of Medicine (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, public-domain)
  • Radboud Repository (Radboud University) (submittedVersion, public-domain)
  • eScholarship (California Digital Library) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • Brigham and Women's Hospital
  • National Institutes of Health (Z99 LM999999, #HHSN261200800001E, HHSN261200800001C)
  • School of Medicine, Stanford University
  • University of North Carolina at Chapel Hill
  • University of California, San Francisco
  • National Human Genome Research Institute (U41HG009650, U41HG006834, U01HG007436, U01HG007437)
  • National Cancer Institute (HHSN261200800001E))
  • National Institute of Environmental Health Sciences (P30ES013508)
  • National Institute of Child Health and Human Development
  • U.S. National Library of Medicine (T15LM007124)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN261200800001E)
  • School of Medicine, University of California, San Francisco
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
ClinGen, variant interpretation, hypertrophic cardiomyopathy, sudden cardiac death, variant reclassification, genetic testing, family screening, genotype-phenotype correlation
MeSH terms
Genetic Testing, Humans, National Library of Medicine (U.S.), United States, Genetic Variation, Genome, Human, Genetic Predisposition to Disease, Genetic Diseases, Inborn, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review